Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer:current clinical trials and prospective challenges
作者机构：Department of Thoracic OncologyCancer CenterWest China HospitalSichuan UniversityChengdu 610041China Department of UrologyInstitute of Urology(Laboratory of Reconstructive Urology)West China HospitalSichuan UniversityChengdu 610041China Department of Radiation OncologyThomas Jefferson UniversityPhiladelphiaPA 19107USA
出 版 物：《Precision Clinical Medicine》 (精准临床医学（英文）)
年 卷 期：2019年第2卷第1期
页 面：57-70页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：supported by the National Natural Science Foundation of China(grant numbers:81872478) Sichuan Provincial Research Foundation for Basic Research(grant numbers:2018JY0550)
主 题：immunotherapy radiotherapy combination immune checkpoints non-small cell lung cancer
摘 要：Lately,the success of ICIs has drastically changed the landscape of cancer treatment,and several immune checkpoint inhibitors(ICIs)have been approved by the US Food and Drug Administration(FDA)for advanced non-small cell lung cancer(NSCLC).However,numerous patients are resistant to ICIs and require additional procedures for better efficacy ***,combination therapy is urgently needed to strengthen the anti-tumor immunity.A variety of preclinical and clinical studies combining ICIs with radiotherapy(RT)have demonstrated that the combination could induce synergistic effects,as RT overcomes the resistance to ***,the underlying mechanism of the synergistic effect and the optimal arrangement of the combination therapy are indecisive ***,this review was conducted to provide an update on the current clinical trial results and highlighted the ongoing *** also discussed the optimal parameters in clinical trials,including radiation dose,radiation fractionation,radiation target field,and sequencing of combination *** this review,we found that combination therapy showed stronger anti-tumor immunity with tolerable toxicities in clinical ***,the best combination mode and potential biomarkers for the target patients in combination therapy are still unclear.
维普期刊数据库